A Single-dose Study of Intranasal Ketorolac in the Treatment of Pain Secondary to Dental Impaction Surgery

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the analgesic efficacy of a single intranasal (IN) administration of ketorolac after dental impaction surgery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Egalet Ltd; Luitpold Pharmaceuticals
• Treatments: Ketorolac; Ketorolac Tromethamine

Criteria

Inclusion Criteria:

• Men or women, age 18 years or older.

• Body weight > or = to 100 pounds and < or = 300 pounds.

• Women of childbearing potential must have a negative serum pregnancy test result prior to entry into the study.

• Able to provide written informed consent.

• At least moderate pain as determined by a PI score of > or = to 50 mm on a 100-mm VAS.

• Willing and able to comply with all testing and requirements defined in the protocol.

• Willing and able to complete the posttreatment visit.

• Immediately prior to entering the study, surgical removal of 3 or 4 third molars (at least 1 mandibular partial bony or complete bony impaction).

Exclusion Criteria:

• Allergy or sensitivity to ketorolac or EDTA.

• Allergic reaction to aspirin or other NSAIDs.

• Current upper respiratory tract infection or other respiratory tract condition that could interfere with the absorption of the nasal spray or with the assessment of adverse events (AEs).

• Use of any IN product within 24 hours prior to study entry.

• Clinically significant abnormality on screening laboratory tests.

• History of cocaine use resulting in nasal mucosal damage.

• Active peptic ulcer disease, recent (defined as within 6 months) history of peptic ulcer disease or gastrointestinal bleeding considered by the investigator to be clinically significant.

• Advanced renal impairment (serum creatinine >1.5 mg/dL) or a risk for renal failure due to volume depletion.

• A history of any other clinically significant medical problem, which in the opinion of the investigator would interfere with study participation.

• Participation within 30 days of study entry or within 5 times the half- life, whichever is longer, in another investigational drug study.

• Pregnancy or breastfeeding.

• Extraction of teeth other than third molars during the surgical procedure; exceptions:(1) supernumerary third molars; (2) cases whereby extraction of a third molar requires the removal of an adjacent molar.

• Previous participation in this study.

• Use of any short-acting NSAID (such as aspirin or ibuprofen) or acetaminophen within 12 hours of surgery.

• Use of longer-acting NSAIDs (such as naproxen sodium) within 48 hours of surgery or piroxicam within 7 days of surgery.

• Use of steroids (other than oral contraceptives) within 72 hours of surgery.

• Use of mood-altering drugs, such a cannabis or alcohol, within 12 hours of surgery.

• Surgical anesthesia including narcotic agents except fentanyl. Short-acting anesthetics, both DEA scheduled and unscheduled, were allowed. Naloxone in any form was not permitted.

• Use of any other medication within 24 hours prior to surgery that, in the opinion of the investigator, could confound the subject's efficacy assessments (eg, sedatives, tranquilizers, MAO inhibitors, phenothiazines).

• Consumption of any caffeine-containing products within 4 hours of surgery.